Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

[1]  A. Prasse,et al.  The natural history of progressive fibrosing interstitial lung diseases , 2020, European Respiratory Journal.

[2]  K. Brown,et al.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. , 2020, The Lancet. Respiratory medicine.

[3]  G. Verleden,et al.  Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study , 2020, European Respiratory Journal.

[4]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[5]  M. Kreuter,et al.  Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management , 2019, Current medical research and opinion.

[6]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[7]  M. Kolb,et al.  The natural history of progressive fibrosing interstitial lung diseases , 2019, Respiratory Research.

[8]  Y. Inoue,et al.  Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials , 2019, BMJ Open Respiratory Research.

[9]  Jong Sun Park,et al.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[10]  G. Verleden,et al.  Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study , 2018, Journal of clinical medicine.

[11]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[12]  K. Brown,et al.  What's in a name? That which we call IPF, by any other name would act the same , 2018, European Respiratory Journal.

[13]  D. Huscher,et al.  Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group , 2018, Arthritis Research & Therapy.

[14]  F. Martinez,et al.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go , 2017, American journal of respiratory and critical care medicine.

[15]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[16]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[17]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[18]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[19]  L. Richeldi,et al.  Corticosteroids for idiopathic pulmonary fibrosis. , 2003, The Cochrane database of systematic reviews.

[20]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[21]  K. Flaherty,et al.  Corticosteroids in idiopathic pulmonary fibrosis , 2001, Current opinion in pulmonary medicine.